Medullary carcinoma of the large intestine: a population based analysis.
Medullary carcinoma (MC) of the colorectum is a relatively new histological type of adenocarcinoma characterized by poor glandular differentiation and intraepithelial lymphocytic infiltrate. To date, there has been no epidemiological study of this rare tumor type, which has now been incorporated as a separate entity in the World Health Organization (WHO) classification of colorectal cancers. We used the population-based registries of the Surveillance, Epidemiology and End Results (SEER) database to identify all cases of colorectal MC between 1973 and 2006 and compared them to poorly and undifferentiated colonic adenocarcinomas (PDA and UDA, respectively). We observed that MCs were rare tumors, constituting approximately 5-8 cases for every 10,000 colon cancers diagnosed, with a mean annual incidence of 3.47 (+/-0.75) per 10 million population. Mean age at diagnosis was 69.3 (+/-12.5) years, with incidence increasing with age. MCs were twice as common in females, who presented at a later age, with a lower stage and a trend towards favorable prognosis. MCs were extremely rare among African-Americans. MCs were most common in the proximal colon (74%), where they present at a later age than the sigmoid colon. There were no cases reliably identified in the rectum or appendix. Serum carcinoembryonic antigen levels (CEA) were elevated prior to first course of treatment in 40% of the patients. MCs were more commonly poorly differentiated (72%), with 22% being undifferentiated. MCs commonly presented with Stage II disease, with 10% presenting with metastases. Only one patient presented with N2b disease (>7 positive nodes). Early outcome analyses showed that MCs have 1- and 2-year relative survival rates of 92.7 and 73.8% respectively. Although MCs showed a trend towards better early overall survival, undifferentiated MCs present more commonly with Stage III, with comparatively worse early outcomes.
Thirunavukarasu
Pragatheeshwar
P
UPMC Cancer Pavilion, University of Pittsburgh, Pittsburgh, PA 15232, USA.
Sathaiah
Magesh
M
Singla
Smit
S
Sukumar
Shyam
S
Karunamurthy
Arivarasan
A
Pragatheeshwar
Kothai Divya
KD
Lee
Kenneth K W
KK
Zeh
Herbert
H
Kane
Kevin M
KM
Bartlett
David L
DL
D000230:Adenocarcinoma / Q000453:epidemiology* / Q000208:ethnology / Q000401:mortality / Q000473:pathology; D017677:Age Distribution; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002272:Carcinoembryonic Antigen / Q000097:blood; D018276:Carcinoma, Medullary / Q000453:epidemiology* / Q000208:ethnology / Q000401:mortality / Q000473:pathology; D002454:Cell Differentiation; D015179:Colorectal Neoplasms / Q000453:epidemiology* / Q000208:ethnology / Q000401:mortality / Q000473:pathology; D005006:Ethnicity; D005260:Female; D006801:Humans; D015994:Incidence; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009378:Neoplasms, Multiple Primary / Q000453:epidemiology; D011379:Prognosis; D018426:SEER Program; D017678:Sex Distribution; D012737:Sex Factors; D015996:Survival Rate; D013997:Time Factors; D014481:United States
D002272:Carcinoembryonic Antigen
Am J Clin Pathol. 2005 Jan;123(1):56-65
15762280
Oncology (Williston Park). 2009 Mar;23(3):288-95
19418830
Am J Pathol. 1994 Jul;145(1):148-56
8030745
Hum Pathol. 1999 Jul;30(7):843-8
10414504
J Clin Oncol. 1999 Aug;17(8):2429-38
10561306
Histopathology. 1977 Jan;1(1):77-84
615835
Am J Pathol. 1997 May;150(5):1815-25
9137104
Am J Pathol. 2001 Feb;158(2):527-35
11159189
Hum Pathol. 2009 Mar;40(3):398-404
18992917
J Clin Oncol. 2010 Jan 10;28(2):264-71
19949014
Am J Pathol. 2001 Dec;159(6):2239-48
11733373